Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides

Abstract

Transthyretin amyloidosis (ATTR amyloidosis) is a rare disease that results from the deposition of misfolded transthyretin (TTR) protein from the plasma into tissues as amyloid fibrils, leading to polyneuropathy and cardiomyopathy. IONIS-TTR_Rx (ISIS 420915) is a 2nd-Generation 2′-O-(2-methoxyethyl) modified “2′-MOE” antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. The activity of IONIS-TTR_Rx to decrease TTR protein levels was studied in transgenic mice bearing the Ile84Ser human TTR mutant, in cynomolgus monkeys and in healthy human volunteers. Robust (>80%) reductions of plasma TTR protein were obtained in all three species treated with IONIS-TTR_Rx, which in mice and monkeys was associated with substantial reductions in hepatic TTR RNA levels. These effects were dose-dependent and lasted for weeks post-dosing. In a Phase 1 healthy volunteer study, treatment with IONIS-TTR_Rx for four weeks was well tolerated without any remarkable safety issues. TTR protein reductions up to 96% in plasma were observed. These nonclinical and clinical results support the ongoing Phase 3 development of IONIS-TTR_Rx in patients with ATTR amyloidosis.

• Amyloidosis
• ATTR
• FAC
• familial
• FAP

Acknowledgements

We thank Maheen N. David and Tracy Reigle for providing assistance with manuscript preparation.

Declaration of interest

Elizabeth J. Ackermann, Shuling Guo, Sheri Booten, Sue Freier, Steven G. Hughes, Tae-Won Kim, T. Jesse Kwoh, John Matson, Dan Norris, Rosie Yu, John Su, Andy Watt and Brett P. Monia are employees and shareholders of Ionis Pharmaceuticals, Inc. Merrill D. Benson is a Consultant of Ionis Pharmaceuticals, Inc.

Supplementary material available online